Literature DB >> 8633037

Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5).

J Fujimoto1, M Shiota, T Iwahara, N Seki, H Satoh, S Mori, T Yamamoto.   

Abstract

We have molecularly cloned a cDNA encoding a protein uniquely expressed and hyperphosphorylated at tyrosine residues in a Ki-1 lymphoma cell that contained chromosomal translocation t(2;5). The encoded protein p80 was shown to be generated by fusion of a protein-tyrosine kinase and a nucleolar protein B23/nucleophosmin (NPM). The coding sequence of this cDNA turned out to be virtually identical to that of the fusion cDNA for NPM-anaplastic lymphoma kinase (ALK) previously cloned from the transcript of the gene at the breakpoint of the same translocation. Overexpression of p80 in NIH 3T3 cells induced neoplastic transformation, suggesting that the p80 kinase is aberrantly activated. The normal form of p80 was predicted to be a receptor-type tyrosine kinase on the basis of its sequence similarity to the insulin receptor family of kinases. However, an immunofluorescence study using COS cells revealed that p80 was localized to the cytoplasm. Thus, subcellular translocation and activation of the tyrosine kinase presumably by its structural alteration would cause the malignant transformation. We also showed that a mutant p80 lacking the NPM portion was unable to transform NIH 3T3 cells. Thus, the NPM sequence is essential for the transforming activity, suggesting that the chromosomal translocation is responsible for the oncogenesis. Finally, Shc and insulin receptor substrate 1 (IRS-1) were tyrosine-phosphorylated and bound to p80 in p80-transformed cells. However, mutants of p80 that were defective for binding to and phosphorylation of Shc and insulin receptor substrate 1 could transform NIH 3T3 cells. Association of these mutants with GRB2 was still observed, suggesting that interaction of p80 with GRB2 but not with Shc or IRS-1 was relevant for cell transformation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8633037      PMCID: PMC39508          DOI: 10.1073/pnas.93.9.4181

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  Site-directed mutagenesis of virtually any plasmid by eliminating a unique site.

Authors:  W P Deng; J A Nickoloff
Journal:  Anal Biochem       Date:  1992-01       Impact factor: 3.365

2.  Characterization of the cDNA encoding human nucleophosmin and studies of its role in normal and abnormal growth.

Authors:  W Y Chan; Q R Liu; J Borjigin; H Busch; O M Rennert; L A Tease; P K Chan
Journal:  Biochemistry       Date:  1989-02-07       Impact factor: 3.162

3.  A new technique for the assay of infectivity of human adenovirus 5 DNA.

Authors:  F L Graham; A J van der Eb
Journal:  Virology       Date:  1973-04       Impact factor: 3.616

4.  A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences.

Authors:  D Martin-Zanca; S H Hughes; M Barbacid
Journal:  Nature       Date:  1986 Feb 27-Mar 5       Impact factor: 49.962

5.  A comprehensive set of sequence analysis programs for the VAX.

Authors:  J Devereux; P Haeberli; O Smithies
Journal:  Nucleic Acids Res       Date:  1984-01-11       Impact factor: 16.971

6.  A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction.

Authors:  G Pelicci; L Lanfrancone; F Grignani; J McGlade; F Cavallo; G Forni; I Nicoletti; F Grignani; T Pawson; P G Pelicci
Journal:  Cell       Date:  1992-07-10       Impact factor: 41.582

7.  Involvement of Shc in insulin- and epidermal growth factor-induced activation of p21ras.

Authors:  G J Pronk; A M de Vries-Smits; L Buday; J Downward; J A Maassen; R H Medema; J L Bos
Journal:  Mol Cell Biol       Date:  1994-03       Impact factor: 4.272

8.  Down-regulation of epidermal growth factor receptor correlates with plasminogen activator activity in human A431 epidermoid carcinoma cells.

Authors:  J L Gross; M N Krupp; D B Rifkin; M D Lane
Journal:  Proc Natl Acad Sci U S A       Date:  1983-04       Impact factor: 11.205

9.  Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo.

Authors:  J Yokota; T Yamamoto; K Toyoshima; M Terada; T Sugimura; H Battifora; M J Cline
Journal:  Lancet       Date:  1986-04-05       Impact factor: 79.321

10.  The ltk gene encodes a novel receptor-type protein tyrosine kinase.

Authors:  J J Krolewski; R Dalla-Favera
Journal:  EMBO J       Date:  1991-10       Impact factor: 11.598

View more
  66 in total

1.  Aberrant ALK tyrosine kinase signaling. Different cellular lineages, common oncogenic mechanisms.

Authors:  M Ladanyi
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

2.  Structural basis for the recognition of nucleophosmin-anaplastic lymphoma kinase oncoprotein by the phosphotyrosine binding domain of Suc1-associated neurotrophic factor-induced tyrosine-phosphorylated target-2.

Authors:  Seizo Koshiba; Hua Li; Yoko Motoda; Tadashi Tomizawa; Takuma Kasai; Naoya Tochio; Takashi Yabuki; Takushi Harada; Satoru Watanabe; Akiko Tanaka; Mikako Shirouzu; Takanori Kigawa; Tadashi Yamamoto; Shigeyuki Yokoyama
Journal:  J Struct Funct Genomics       Date:  2010-05-08

3.  A directed screen for genes involved in Drosophila blood cell activation.

Authors:  Carl-Johan Zettervall; Ines Anderl; Michael J Williams; Ruth Palmer; Eva Kurucz; Istvan Ando; Dan Hultmark
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-20       Impact factor: 11.205

4.  Identification and characterization of DAlk: a novel Drosophila melanogaster RTK which drives ERK activation in vivo.

Authors:  C E Lorén; A Scully; C Grabbe; P T Edeen; J Thomas; M McKeown; T Hunter; R H Palmer
Journal:  Genes Cells       Date:  2001-06       Impact factor: 1.891

5.  The slow Wallerian degeneration protein, WldS, binds directly to VCP/p97 and partially redistributes it within the nucleus.

Authors:  Heike Laser; Laura Conforti; Giacomo Morreale; Till G M Mack; Molly Heyer; Jane E Haley; Thomas M Wishart; Bogdan Beirowski; Simon A Walker; Georg Haase; Arzu Celik; Robert Adalbert; Diana Wagner; Daniela Grumme; Richard R Ribchester; Markus Plomann; Michael P Coleman
Journal:  Mol Biol Cell       Date:  2005-12-21       Impact factor: 4.138

Review 6.  Pathobiology of ALK+ anaplastic large-cell lymphoma.

Authors:  Hesham M Amin; Raymond Lai
Journal:  Blood       Date:  2007-05-22       Impact factor: 22.113

7.  NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma.

Authors:  Annamaria Galietta; Rosalind H Gunby; Sara Redaelli; Paola Stano; Cristiana Carniti; Angela Bachi; Philip W Tucker; Carmen J Tartari; Ching-Jung Huang; Emanuela Colombo; Karen Pulford; Miriam Puttini; Rocco G Piazza; Holger Ruchatz; Antonello Villa; Arianna Donella-Deana; Oriano Marin; Danilo Perrotti; Carlo Gambacorti-Passerini
Journal:  Blood       Date:  2007-05-30       Impact factor: 22.113

8.  Malignant transformation of CD4+ T lymphocytes mediated by oncogenic kinase NPM/ALK recapitulates IL-2-induced cell signaling and gene expression reprogramming.

Authors:  Michal Marzec; Krzysztof Halasa; Xiaobin Liu; Hong Y Wang; Mangeng Cheng; Donald Baldwin; John W Tobias; Stephen J Schuster; Anders Woetmann; Qian Zhang; Suzanne D Turner; Niels Ødum; Mariusz A Wasik
Journal:  J Immunol       Date:  2013-11-11       Impact factor: 5.422

9.  p130Cas mediates the transforming properties of the anaplastic lymphoma kinase.

Authors:  Chiara Ambrogio; Claudia Voena; Andrea D Manazza; Roberto Piva; Ludovica Riera; Laura Barberis; Carlotta Costa; Guido Tarone; Paola Defilippi; Emilio Hirsch; Elisabetta Boeri Erba; Shabaz Mohammed; Ole N Jensen; Giorgio Palestro; Giorgio Inghirami; Roberto Chiarle
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

10.  IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma.

Authors:  Jennifer Dien Bard; Pascal Gelebart; Mona Anand; Zoulika Zak; Samar A Hegazy; Hesham M Amin; Raymond Lai
Journal:  Am J Pathol       Date:  2009-07-16       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.